Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesAroa Biosurgery Ltd

Aroa Biosurgery Ltd

Healthcare Medical Devices
PortfolioPortfolio WatchlistWatchlist
Company price
0.53 AUD 0.04 ( 8.16%)
Last update at 2026-11-06T05:10:00Z
VOLUME
553672
Market Cap
171.82M
P/E
49.00

Momentum Score

…

Aroa Biosurgery Limited develops, manufactures, and sells medical devices for wound and soft tissue repair using extracellular matrix (ECM) technology in the United States and internationally. Its products include Endoform Natural and Endoform Antimicrobial Restorative Bioscaffold for treating acute and chronic wounds; Myriad Matrix, an engineered ECM for soft tissue repair, reinforcement, and complex wounds; and Myriad Morcells, Myriad Morcells Fine, Myriad Meshed, and Symphony products for the treatment of partial and full-thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, tunneled/undermined wounds, surgical wounds, trauma wounds, and draining wounds. The company also develops products for abdominal wall reconstruction, hernia repair, and breast reconstruction in North America and Europe. Aroa Biosurgery Limited was incorporated in 2007 and is headquartered in Auckland, New Zealand.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.47
Low
0.53
High
52 Week Price Range
0.47
Low
0.79
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Aroa Biosurgery develops and commercialized regenerative soft-tissue repair products based on extracellular matrix technologies for surgical and wound-care applications. Long-term growth drivers include ageing populations and rising chronic wound and surgical procedure volumes, geographic expansion and additional regulatory clearances, and wider clinical adoption that could support recurring consumable sales; investors may find the company's focused product portfolio and clinical-led commercial approach appealing as it appears positioned to scale revenues over time.
Key investment risks include regulatory and reimbursement uncertainty, strong competition from larger medtech and biologics firms, and execution and financing risk as the company expands its commercial footprint.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.49
Dividend Yield
-
Revenue TTM
103.85M
Revenue Per Share
0.30
Gross Profit TTM
88.83M
Debt / Equity
0.06
ROE
4.86%
Net Debt
-12.23M
ROCE
5.01%
Diluted EPS TTM
0.01

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Type yearly yearly yearly yearly yearly
Date 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Income before tax 3.85M -2.95M -9.56M -0.36M -7.68M
Net income 4.16M -3.47M -9.75M -0.37M -7.79M
Selling general administrative - 60.93M 0.60M 47.71M 28.54M
Selling and marketing expenses - 60.93M 57.01M 44.66M 28.54M
Gross profit 79.63M 65.99M 54.10M 50.06M 28.17M
Reconciled depreciation - 4.49M 4.03M 3.59M 2.91M
Ebit 4.36M -1.85M -9.79M -0.35M -6.98M
Ebitda 9.03M 2.65M -6.78M 3.24M -4.07M
Depreciation and amortization 4.67M 4.49M 3.00M 3.59M 2.91M
Operating income 4.36M -8.13M -9.79M -0.35M -6.98M
Other operating expenses 87.92M 85.10M 78.70M 67.44M 47.93M
Interest expense 0.42M 0.44M 1.16M 0.01M 0.70M
Tax provision - 0.51M 0.18M 0.01M 0.12M
Interest income - 0.96M 1.65M 2.73M 0.37M
Net interest income - -0.58M 0.04M 0.87M -0.70M
Income tax expense -0.31M 0.51M 0.18M 0.01M 0.12M
Total revenue 92.28M 76.97M 63.36M 59.31M 36.88M
Total operating expenses 75.27M 74.12M 69.45M 58.19M 39.22M
Cost of revenue 12.66M 10.98M 9.26M 9.25M 8.72M
Total other income expense net -0.51M 5.17M 0.22M 3.30M 1.16M
Net income from continuing ops - -3.47M -9.75M -0.37M -7.79M
Net income applicable to common shares - -3.81M -10.63M -0.40M -8.39M
Breakdown 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Type yearly yearly yearly yearly yearly
Date 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Total assets 100.48M 98.94M 101.82M 109.07M 104.71M
Intangible assets 11.56M 12.33M - 11.31M 10.90M
Other current assets 2.91M 19.47M 1.66M 10.36M 1.23M
Total liab 17.74M 14.35M 14.78M 13.69M 11.30M
Total stockholder equity 82.74M 84.59M 87.04M 95.38M 93.40M
Deferred long term liab - - - 1.33M -
Other current liab 7.38M 6.83M 6.24M 5.10M 4.45M
Common stock 122.53M 133.44M 134.59M 137.13M 135.47M
Capital stock - 133.44M - 137.13M 135.47M
Retained earnings -44.82M -58.21M -56.98M -48.23M -47.52M
Other liab - - - - 0.16M
Good will 4.61M 5.03M 5.08M 5.18M 5.15M
Other assets - - - 0.13M 0.15M
Cash 17.54M 7.26M 10.56M 8.93M 5.73M
Total current liabilities 13.50M 9.36M 8.72M 7.41M 6.24M
Current deferred revenue - - 0.00M - -
Net debt -12.23M -1.43M -3.75M -2.28M -0.27M
Short term debt 1.23M 1.02M 0.92M 0.52M 0.55M
Short long term debt total 5.31M 5.83M 6.82M 6.65M 5.46M
Other stockholder equity - - 0.00M 0.00M 5.86M
Property plant equipment - - - 20.64M 15.36M
Total current assets 64.37M 61.95M 63.29M 73.14M 74.24M
Net tangible assets - - - 85.60M 83.22M
Short term investments 5.06M 12.87M 17.15M 34.07M 47.62M
Net receivables 33.84M 14.84M 26.49M 13.41M 15.96M
Inventory 5.01M 7.52M 7.43M 4.52M 3.70M
Accounts payable 4.88M 1.51M 1.57M 1.79M 1.24M
Accumulated other comprehensive income 5.03M 9.36M 9.44M 6.48M 5.45M
Non currrent assets other 0.05M 0.07M 13.08M 0.12M 0.14M
Non current assets total 36.12M 36.98M 38.53M 35.93M 30.46M
Capital lease obligations - 5.83M - 6.65M 5.46M
Long term debt total - - - 6.55M 5.29M
Breakdown 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Type yearly yearly yearly yearly yearly
Date 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Investments - 0.27M 9.31M 6.79M -30.00M
Change to liabilities - - - - 1.32M
Total cashflows from investing activities 3.80M 0.27M 9.31M 7.25M -34.87M
Net borrowings - - - - -10.09M
Total cash from financing activities -1.55M -1.34M -0.95M -0.47M 34.98M
Change to operating activities - - - - -1.34M
Net income 4.16M -3.47M -9.85M -0.37M -8.39M
Change in cash 10.28M -3.21M 1.82M 3.16M -8.57M
Begin period cash flow 7.26M 10.47M 8.75M 5.77M 14.30M
End period cash flow 17.54M 7.26M 10.57M 8.93M 5.73M
Total cash from operating activities 9.37M -2.33M -6.76M -3.77M -11.52M
Issuance of capital stock - 0.01M 0.18M 0.49M 46.77M
Depreciation 4.67M - 4.09M - 3.13M
Other cashflows from investing activities - -1.26M -3.18M 14.87M -30.00M
Change to inventory 2.00M -0.15M -3.03M - -0.32M
Change to account receivables -5.07M -2.63M 0.81M - -10.39M
Sale purchase of stock - -1.35M -1.13M -0.96M -2.06M
Other cashflows from financing activities -1.62M 0.92M -0.45M 0.00M -0.90M
Change to netincome - - - - 4.32M
Capital expenditures 0.99M 3.36M 3.23M 7.12M 4.53M
Change in working capital -0.84M -6.93M -6.23M 1.17M 0.14M
Stock based compensation - - 2.92M - -
Other non cash items 1.38M 4.60M 9.32M - -
Free cash flow 8.39M -5.69M -10.00M -7.12M -4.53M

Peer Comparison*

Sector: Healthcare Industry: Medical Devices

Stock Name
Change
(AUD)
Price
(AUD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
ARX
Aroa Biosurgery Ltd		 0.04
8.16%		 0.53 49.00 60.24 1.65 2.07 1.78 15.57
COH
Cochlear Ltd		 1.03
0.67%		 155.47 68.64 27.40 4.30 5.34 3.97 28.09
IMR
Imricor Medical Systems Inc		 -0.03
2.29%		 1.28 - - 36401.21 17.45 4019.33 -2.60
AVR
Anteris Technologies Global Corp		 -0.36
4.21%		 8.20 - - 356.02 2.19 130.34 -5.20
AVH
Avita Medical Inc		 -0.08
1.73%		 4.55 - 9.97 9.59 7.17 6.76 15.37

Profile*

Aroa Biosurgery Ltd

Aroa Biosurgery Limited develops, manufactures, and sells medical devices for wound and soft tissue repair using extracellular matrix (ECM) technology in the United States and internationally. Its products include Endoform Natural and Endoform Antimicrobial Restorative Bioscaffold for treating acute and chronic wounds; Myriad Matrix, an engineered ECM for soft tissue repair, reinforcement, and complex wounds; and Myriad Morcells, Myriad Morcells Fine, Myriad Meshed, and Symphony products for the treatment of partial and full-thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, tunneled/undermined wounds, surgical wounds, trauma wounds, and draining wounds. The company also develops products for abdominal wall reconstruction, hernia repair, and breast reconstruction in North America and Europe. Aroa Biosurgery Limited was incorporated in 2007 and is headquartered in Auckland, New Zealand.

64 Richard Pearse Drive, Auckland, New Zealand, 2022

64 9 869 3035

https://aroa.com

Name Title Year Born
Dr. Brian Ward Founder, CEO, MD & Exec. Director NA
Mr. James Agnew BCom, LLB CFO & Joint Company Sec. NA
Dr. Barnaby C.H. May Ph.D. Chief Scientific Officer NA
Ms. Tracy Weimar BA, MBA Company Sec. NA
Dr. Brian Ward Founder, CEO, MD & Executive Director NA
Mr. James Agnew BCom, LLB CFO & Joint Company Secretary NA
Mr. Scott Sherriff B.A., M.B.A. Chief Operating Officer NA
Ms. Neetha Alex-Kumar General Counsel NA
Mr. Frazer Murray Director of Global Marketing & Strategy NA
Ms. Yasmin Winchester B.Sc. Vice President of Quality, Regulatory & Sustainability NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…